Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

883
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
883
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.4K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.4K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

715
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
715
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.2K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.5K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.5K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Furoxan derivatives with antimalarial activity that disrupt P. falciparum endoplasmic reticulum calcium homeostasis.

International journal for parasitology. Drugs and drug resistance·2026
Same author

From Epigenetic Regulation to Protein Degradation: Emerging Strategies for Anti-Infective Drug Discovery.

International journal of molecular sciences·2026
Same author

Photoprotection of a novel resveratrol analogue: insights from 2D, 3D, and endothelialized bioprinted human skin models.

Frontiers in pharmacology·2026
Same author

Targeting nitroreductases for selective drug activation: therapeutic perspectives in neglected diseases and tuberculosis.

Bioorganic chemistry·2025
Same author

Ozonized Sunflower Oil: Standardization and Mechanisms of the Antimicrobial Effect.

International journal of molecular sciences·2025
Same author

The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes.

Journal of the American Chemical Society·2025

Related Experiment Video

Updated: Apr 4, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Tuberculosis: Challenges to Improve the Treatment.

Mariana Moreira Lima, Ariane Trindade, Flávia Carnavalli

  • 1State University of São Paulo "Júlio de Mesquita Filho" -UNESP, School of Pharmaceutical Science, Drugs and Medicines Departament, Center of Pharmaceutical Care (NAF), Rodovia Araraquara Jaú Km, 01, 14801-902 Araraquara, SP, Brazil. santosjl@fcfar.unesp.br.

Current Clinical Pharmacology
|September 5, 2015
PubMed
Summary

Tuberculosis treatment faces significant hurdles including drug resistance and HIV co-infection. This review explores these challenges and proposes strategies for improved tuberculosis management.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 4, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Tuberculosis (TB) remains a major global health concern, causing significant morbidity and mortality.
  • Current TB treatment regimens are challenged by the rise of multi-drug resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains.
  • HIV co-infection further complicates TB management, increasing treatment difficulty and mortality rates.

Purpose of the Study:

  • To comprehensively review the primary obstacles encountered in contemporary tuberculosis treatment.
  • To identify and discuss innovative strategies aimed at enhancing the efficacy and success of TB therapy.

Main Methods:

  • Systematic literature review of current research on tuberculosis treatment challenges.
  • Analysis of patient-related, treatment-related, and healthcare system-related factors impacting TB outcomes.
  • Synthesis of evidence-based strategies for overcoming treatment barriers.

Main Results:

  • Identified key challenges including drug resistance, treatment adherence issues, and healthcare system inefficiencies.
  • Highlighted the negative impact of HIV co-infection on TB treatment outcomes.
  • Documented various proposed strategies for improving TB treatment protocols and patient management.

Conclusions:

  • Addressing drug resistance and co-infections is critical for effective TB control.
  • Multifaceted strategies involving patients, healthcare providers, and health systems are necessary to improve TB treatment outcomes.
  • Continued research and implementation of novel approaches are essential to combat the global tuberculosis epidemic.